LAMTOR5 and breast cancer: As shown in Fig. 4C and Supplementary Fig. 2A, HBXIP or Nrf2 knockdown (or overexpression) and simultaneous HBXIP and Nrf2 knockdown (or overexpression) significantly upregulated (or downregulated) intracellular ROS levels and mtROS levels, enhanced (or attenuated) mitochondrial permeabilization, decreased (or increased) levels of the two most abundant antioxidants GSH and NADPH, and attenuated (or enhanced) ATP production in breast cancer cells following ECM detachment (Fig. 4C and Supplementary Fig. 2A).